Rheumatology is facing a clinician shortage, so attracting the right candidate for your practice may require an aggressive strategy, from recruiting right out of fellowship programs to offering student loan repayment and flexible work schedules…
Trump Healthcare Order Could Face Strong Legal Objections
(Reuters)—U.S. President Donald Trump’s expected plan to let Americans buy insurance across state lines could violate federal law governing employee benefit plans and will almost certainly be challenged in court, several legal experts said. Trump said on Tuesday he would likely sign an executive order this week allowing people to cross state lines to obtain…
Frustrated by Congress, Trump Signs Order to Weaken Obamacare
WASHINGTON (Reuters)—President Donald Trump on Thursday signed an order to make it easier for Americans to buy bare-bones health insurance plans, using his presidential powers to undermine Obamacare after fellow Republicans in Congress failed to repeal the 2010 law. Trump issued the executive order aimed at letting small businesses band together across state lines to…
Flexion’s Knee Pain Drug Gets FDA Approval
(Reuters)—Flexion Therapeutics Inc. said its injectable drug to treat osteoarthritis-related knee pain was approved by the U.S. Food and Drug Administration. The approval comes at a time when U.S. federal authorities are implementing a slew of measures to combat opioid abuse, with President Donald Trump in August declaring the opioid epidemic a national emergency. The…
New Data May Explain the Role of Sclerostin in Bone Formation
New research in mice shows that sclerostin deficiency may play a significant role in bone formation, possibly despite skeletal age. In the study, sclerostin-deficient mice more readily formed cortical bone and had increases in periosteal bone formation rates, as well as increased expression of the Wnt inhibitor Dkk1, than controls…
The Right Way to Network
In addition to outstanding educational sessions, the 2017 ACR/ARHP Annual Meeting offers an opportunity to make connections and build relationships…
Secukinumab Meets 5-Year Benchmark for Psoriasis
In an extension study, nearly half the patients with plaque psoriasis taking secukinumab maintained skin clearance for the five years of the study…
Senator McCaskill Drafts Bill in Response to Allergan Patent Maneuver
NEW YORK (Reuters)—Democratic U.S. Senator Claire McCaskill on Thursday said she drafted a bill stating that tribal sovereign immunity cannot be used to block U.S. Patent and Trademark Office review of a patent. Drugmaker Allergan Plc made a deal to transfer some of its patents to a Native American tribe two weeks ago in order…
New Jersey Sues Insys as Opioid Maker Settles with Massachusetts
BOSTON (Reuters)—New Jersey on Thursday accused Insys Therapeutics Inc of engaging in a fraudulent scheme to boost sales of a fentanyl-based cancer pain drug, as Massachusetts announced a $500,000 settlement with the drugmaker to resolve similar allegations. The lawsuit by New Jersey Attorney General Christopher Porrino accused Insys of illegally directing its sales force to…
Cigna to End OxyContin Painkiller Coverage, Signs Contract for Alternative
(Reuters)—Amid a growing U.S. opioid addiction, health insurer Cigna Corp will stop covering OxyContin, the opioid painkiller sold by Purdue Pharma LP, as of January 1 and will instead cover an equivalent with a formulation less vulnerable to abuse, the company said on Wednesday. The insurer has signed a “value-based contract” with Collegium Pharmaceutical Inc…
- « Previous Page
- 1
- …
- 397
- 398
- 399
- 400
- 401
- …
- 820
- Next Page »